Srinivas Akkaraju bought $5.0M of Kalaris Therapeutics (KLRS)
Executed Dec 18 2025, disclosed Feb 18, 61 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Feb 17), the stock returned -14.5% (delay-adjusted); from the execution session (Dec 18 2025), -9.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Srinivas Akkaraju (Director) filed 12 Form 4 reports in the trailing twelve months (12 purchases, 1 sale, 2 filed past the two-business-day deadline; 1 filing reported both), most often in Alumis Inc. (ALMS). Across 11 priced purchase filings, the average 21-session return was +35.0% from execution and +27.3% from disclosure (delay-adjusted; derived). The largest single filing was $11.9M of SRRK (287,970 sh across 4 lots, as filed), executed Oct 23.
Healthcare · Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→244,300 sh × $4.83
Exec May 20
Filed May 22 · 7:47 PM ET